

Certificate of Analysis

Print Date: Nov 27th 2018

www.tocris.com

Product Name: PL 017 Catalog No.: 2024 Batch No.: 2

CAS Number: 83397-56-2

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{29}H_{37}N_5O_5$ **Batch Molecular Weight:** 535.64

White lyophilised solid **Physical Appearance:**

Net Peptide Content: 71% Counter Ion: **TFA**

Solubility: Soluble to 1 mg/ml in water

Store at -20°C Storage:

Peptide Sequence: Tyr-Pro-NMe-Phe-D-Pro-NH2

2. ANALYTICAL DATA

HPLC: Shows 99.6% purity Mass Spectrum: Consistent with structure

3. AMINO ACID ANALYSIS DATA

Amino	Acid 7	Theoretica	ıl Actual	Amino	Acid T	heoretica	I Actua	al

Ala	Lys		
Arg	Met		
Asx	Phe		
Cys	Pro	2.00	2.01
Glx	Ser		
Gly	Thr		
His	Trp		
lle	Tyr	1.00	0.99
Leu	Val	1.00	Detected

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Tel: +44 (0)1235 529449



Product Information

Print Date: Nov 27th 2018

www.tocris.com

Product Name: PL 017 Catalog No.: 2024 Batch No.: 2

CAS Number: 83397-56-2

Description:

Selective μ opioid receptor agonist (IC $_{50}$ values are 5.5 and > 10000 nM for inhibition of 125 I-FK 33,824 and 125 I-DADLE binding to μ and δ sites respectively). Produces naloxone-reversible analgesia, catalepsy and hyperthermia following central administration in rats in vivo.

Physical and Chemical Properties:

Batch Molecular Formula: C₂₉H₃₇N₅O₅ Batch Molecular Weight: 535.64

Physical Appearance: White lyophilised solid

Peptide Sequence:

Tyr-Pro-NMe-Phe-D-Pro-NH2

Storage: Store at -20°C

Solubility & Usage Info:

Soluble to 1 mg/ml in water

This product is supplied as a lyophilized solid and may be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

Net Peptide Content: 71% (Remaining weight made up of counterions and residual water).

Counter Ion: TFA

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Peptides in solution are much less stable than in lyophilized form. This is especially true for peptides whose sequences contain amino acids such Cys, Met,Trp, Asn, Gln, and N-terminal Glu.

Therefore we recommend storing peptides in solution for as short a time as possible. Avoid repeated freeze thaw cycles by dividing the peptide solution into aliquots and storing the aliquots at -20°C. Any portion of an aliquot unused after thawing should be discarded.

Peptides stored in solution can occasionally be susceptible to bacterial degradation. We recommend using sterile solutions or passing the peptide solution through a 0.2 μ m filter to remove potential bacterial contamination whenever possible.

References:

Xin *et al* (1997) Body temperature and analgesic effects of selective mu and kappa opioid receptor agonists microdialyzed into rat brain. J.Pharmacol.Exp.Ther. **281** 499. PMID: 9103537.

Meyer and Meyer (1993) Behavioral effects of the μ -opioid peptide agonists DAMGO, DALDA and PL017 on locomotor activities. Pharmacol.Biochem.Behav. **46** 391. PMID: 8265694.

Chang et al (1983) Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J.Pharmacol.Exp.Ther. 227 403. PMID: 6313901.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use